Liaw Y S, Yang P C, Yu C J, Chang D B, Wang H J, Lee L N, Kuo S H, Luh K T
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China.
J Clin Microbiol. 1995 Jun;33(6):1588-91. doi: 10.1128/jcm.33.6.1588-1591.1995.
Pulmonary cryptococcosis causes significant morbidity and mortality in immunocompromised patients. Definitive diagnosis of pulmonary cryptococcosis is usually difficult. The use of direct determination of cryptococcal antigen in transthoracic needle aspirate to diagnose pulmonary cryptococcosis was investigated. Over a 2-year period, we studied a total of 41 patients with respiratory symptoms and pulmonary infiltrates of unknown etiology who were suspected of having pulmonary cryptococcosis. Twenty-two patients were immunocompetent patients and 19 patients were immunocompromised. A diagnosis of pulmonary cryptococcosis was based on cytological examination, culture for Cryptococcus neoformans, histopathologic examination, and clinical response to antifungal therapy. All patients underwent chest ultrasound and ultrasound-guided percutaneous transthoracic needle aspiration to obtain specimens for cryptococcal antigen determination. The presence of cryptococcal antigen was determined by the latex agglutination system (CALAS; Meridian Diagnostics, Cincinnati, Ohio). An antigen titer equal to or greater than 1:8 was considered positive. The specimens were also sent for cytological examination, fungal culture, and/or histopathologic examination. A final diagnosis of pulmonary cryptococcosis was made in eight patients. Direct determinations of cryptococcal antigen in lung aspirate were positive in all eight patients with pulmonary cryptococcosis (100% sensitivity, 97% specificity, a positive predictive value of 89%, and negative value of 100%), and there was only one false-positive in noncryptococcosis patients. The diagnostic accuracy was 97.5%. Serum cryptococcal antigen was positive in only three patients with pulmonary cryptococcosis (sensitivity, 37.5%). This study showed that direct measurement of cryptococcal antigen in lung aspirate can be a rapid and useful test for diagnosis of pulmonary cryptococcosis.
肺隐球菌病在免疫功能低下患者中可导致显著的发病率和死亡率。肺隐球菌病的明确诊断通常较为困难。本研究探讨了经胸针吸活检直接检测隐球菌抗原在肺隐球菌病诊断中的应用。在两年时间里,我们共研究了41例有呼吸道症状且肺部有不明原因浸润、疑似患有肺隐球菌病的患者。其中22例为免疫功能正常患者,19例为免疫功能低下患者。肺隐球菌病的诊断基于细胞学检查、新型隐球菌培养、组织病理学检查以及对抗真菌治疗的临床反应。所有患者均接受胸部超声检查及超声引导下经皮经胸针吸活检,以获取标本进行隐球菌抗原检测。采用乳胶凝集系统(CALAS;Meridian Diagnostics公司,俄亥俄州辛辛那提)检测隐球菌抗原的存在。抗原滴度等于或大于1:8被视为阳性。标本还被送去进行细胞学检查、真菌培养和/或组织病理学检查。最终8例患者被诊断为肺隐球菌病。所有8例肺隐球菌病患者的肺穿刺液隐球菌抗原直接检测均为阳性(敏感性100%,特异性97%,阳性预测值89%,阴性预测值100%),非隐球菌病患者仅出现1例假阳性。诊断准确性为97.5%。仅3例肺隐球菌病患者血清隐球菌抗原呈阳性(敏感性37.5%)。本研究表明,肺穿刺液中隐球菌抗原的直接检测可作为诊断肺隐球菌病的快速且有用的检测方法。